Benefit-risk assessment: the use of clinical utility index. - Wikidata - wikimedia - TriplyDB

Benefit-risk assessment: the use of clinical utility index.

Benefit-risk assessment: the use of clinical utility index.

http://www.wikidata.org/entity/Q37696499

about

Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine Integration of PKPD relationships into benefit-risk analysis A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles.Payers and the assessment of clinical utility for companion diagnostics.Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis.Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.

P2860

Q28661424-C62AB0D0-A004-4FAA-A049-C3A05AE04E8B Q30671571-6106A803-2164-493A-BF32-1A609C6A70EF Q33434352-76669105-AA36-4732-8027-324370954C45 Q37256647-A0572974-6C01-4E05-B14D-21B517410C48 Q37809963-7C9D5229-1951-4123-87CA-4AE050D27004 Q38211405-494446C7-6CD0-4ADA-85A2-92117B5D6D7B Q38917477-D503BB4C-F6C8-4342-BC72-F6BA9ADD4F0A Q39134309-7B6F770C-CCCD-4189-BFFA-7713A6BEBC75 Q45057327-1E18158A-CCAE-4798-8BD6-45BCE2140231

P2860

Benefit-risk assessment: the use of clinical utility index.

http://www.wikidata.org/entity/Q37696499

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Benefit-risk assessment: the use of clinical utility index.

@en

Benefit-risk assessment: the use of clinical utility index.

@nl

type

label

Benefit-risk assessment: the use of clinical utility index.

@en

Benefit-risk assessment: the use of clinical utility index.

@nl

prefLabel

Benefit-risk assessment: the use of clinical utility index.

@en

Benefit-risk assessment: the use of clinical utility index.

@nl

P1433

Q37696499-B489FD6D-F539-4001-AFF5-844701233C8F

P1476

Q37696499-0F3BFC0B-A51A-4728-ABF1-492335B99CA4

P2093

Q37696499-56625F79-7F9B-4AA8-830B-63747AB696EC

P2860

Q37696499-0909E2C8-CD82-4DA1-91E4-8A09387E6726

Q37696499-1710748A-DC09-4EFC-A395-FBD4D17D8EAB

Q37696499-1A8A972F-3B61-492A-87C5-2E8F61DD4B2A

Q37696499-20ADD185-BFD6-4E57-92AB-94FB154C1A50

Q37696499-289573D1-C88A-452E-91B6-26D409B49E7C

Q37696499-2907571B-F777-4A9F-BC86-A8A31B310FD3

Q37696499-29C3F9CE-7C8D-403B-AF3A-E510FF3596C7

Q37696499-318C1E25-1D1F-48D4-A98D-96CEF53F1B54

Q37696499-3F7E0549-99FA-48FF-BF42-8E900EE2ACEB

Q37696499-41273336-4D03-43D8-8833-4F73053CC5B7

P304

Q37696499-270626E1-215E-4F6F-8436-B19B9477D9D9

P31

Q37696499-DF1C0158-FD5A-427A-9C9F-C5CC54A183B5

P356

Q37696499-75D7D5F8-619F-42DA-A5C7-8965F793245A

P407

Q37696499-9C48AC76-0B2E-4D45-83B7-68D0CFF30804

P433

Q37696499-5818E689-17FD-4FAF-9694-9AA354B68359

P478

Q37696499-9F274948-2B81-4798-A055-4D941D69B21F

P577

Q37696499-DA9FA0F4-42AF-4144-A647-15C530DFFE27

P698

Q37696499-A3855F87-AEEB-47E0-818F-AA343E806B12

P356

14740330903499265

P1433

Expert Opinion on Drug Safety

P1476

Benefit-risk assessment: the use of clinical utility index.

@en

P2093

Daniele Ouellet

http://www.w3.org/2001/XMLSchema#string

P2860

Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data.

A two-part mixture model for longitudinal adverse event severity data.

Combining drug-disease and economic modelling to inform drug development decisions.

Model-based development of gemcabene, a new lipid-altering agent.

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Paving the critical path: how can clinical pharmacology help achieve the vision?

Model-based drug development.

The use of clinical utility assessments in early clinical development

Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation.

Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

P304

289-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740330903499265

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20175698

http://www.w3.org/2001/XMLSchema#string